Kura Oncology (KURA) 10-Q 2019 Q3 Quarterly report

Exhibit 10.2

Kura Oncology, Inc.

First Amendment to

Executive Employment Agreement

This First Amendment to Executive Employment Agreement(this “Amendment”), amending that certain Executive Employment Agreement (the “Employment Agreement”), effective as of August 21, 2018, by and between Kura Oncology, Inc. (the “Company”) and Marc Grasso, M.D.(the “Executive”), is entered into effective as of August 21, 2018.  

RECITALS

Whereas, the Company and the Executive have previously entered into the Employment Agreement; and

Whereas, the Company and the Executive desire to amend the Employment Agreement as set forth herein.

AGREEMENT

Now, Therefore, in consideration of the foregoing and the promises and covenants contained herein and in the Employment Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows:

1.Section 6.2(a)(ii) of the Employment Agreement.  The reference to “9 months” contained in Section 6.2(a)(ii) of the Employment Agreement is hereby amended and restated such that it shall be “12 months.”

2.Effect of Amendment.  Except as expressly modified by this Amendment, the Employment Agreement shall remain unmodified and in full force and effect.

3.Governing Law.  This Amendment shall be governed by the laws of the State of California, without regard to any conflicts of law principals thereof that would call for the application of the laws of any other jurisdiction.

4.Counterparts.  This Amendment may be executed via facsimile or electronic (i.e., PDF) transmission and in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument.

[Remainder of Page Intentionally Left Blank]

1

In Witness Whereof, the parties have executed this First Amendment to Executive Employment Agreementas of the date first written above.

COMPANY:

Kura Oncology, Inc.

By:     /s/ Troy E. Wilson, Ph.D., J.D.

Name:      Troy E. Wilson, Ph.D., J.D.

Title:         President and CEO

EXECUTIVE:

/s/ Marc Grasso, M.D.

Marc Grasso, M.D.